基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于 RAD51 的同源重组缺陷与早期乳腺癌的治疗反应和生存相关
英文原题：RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.
查看英文原题
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
乳腺癌（BC）治疗的进展受限于缺乏成熟的DNA损伤靶向治疗生物标志物。我们在疑似胚系易感性的早期BC患者中，评估了通过RAD51核灶和间质TIL（肿瘤浸润淋巴细胞）（TILs）检测的同源重组修复（HRR）缺陷（HRD）的预测和预后价值。在291例患者中，78.4%的肿瘤存在基于RAD51的HRD，69.8%的患者TILs较低（<30%）。在178例接受新辅助化疗的患者中，HRD肿瘤相比HRR正常（HRP）肿瘤具有更高的病理完全缓解（pCR）率（52.3% vs 36.4%）；RAD51仍与pCR独立相关（p = 0.03）。总生存期（OS）倾向于HRD，5年OS为89.2% vs HRP的82.8%（p = 0.009），在三阴性TILs低表达疾病中证据更强（p = 0.005）。这些发现支持基于RAD51的HRD评估作为一种预测和预后生物标志物，可能指导早期BC的治疗决策。
展开英文摘要原文
Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments.
We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.
4% of tumours, and 69. 8% had low TILs (<30%). In 178 patients treated with neoadjuvant chemotherapy, pathologic complete response (pCR) was higher in those with HRD vs HRR-proficient (HRP) tumours (52. 3% vs 36. 4%); RAD51 remained independently associated with pCR (p = 0. 03).
Overall survival (OS) favoured HRD, with 5-year OS of 89. 2% vs 82. 8% in HRP (p = 0. 009), with stronger evidence in triple-negative TILs-low disease (p = 0. 005).
These findings support RAD51-based HRD assessment as a predictive and prognostic biomarker that may guide treatment decisions in early-stage BC.
论文信息
- 作者
- Llop-Guevara A、Pellegrino B、Pimentel I、Villacampa G、Solinas C、Torres-Esquius S、Campanini N、Simonetti S
- 第一作者单位
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.Spain
- 通讯作者单位
- Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain. jbalmana@vhio.net.Spain
- 期刊
- NPJ breast cancer2026 Mar 5
- 原文标识
- PubMed 41786739 · DOI 10.1038/s41523-026-00920-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →